IntoCell, Inc. Stock

A287840

KR7287840003

Biotechnology & Medical Research

End-of-day quote Korea S.E. 16/10/2026			5-day change	1st Jan Change
14,890.00 ^KRW	+10.30%		-14.03%	-74.06%

07-23	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
12-22	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI

IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	₩14,890.00	+10.30%	60,160
15/10/26	₩13,500.00	-6.12%	58,061
14/10/26	₩14,380.00	-2.64%	40,925
13/10/26	₩14,770.00	-6.58%	51,414
12/10/26	₩15,810.00	-8.72%	41,595

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - IntoCell, Inc.

Company calendar

Market Cap	224B 168M 149M 138M 126M 237M 15.98B 241M 1.66B 652M 8.33B 631M 618M 26.56B	P/E 2024 *	-	P/E 2025	-77.1x
Enterprise Value	203B 153M 135M 126M 114M 215M 14.5B 219M 1.51B 592M 7.56B 573M 561M 24.11B	EV / Sales 2024 *	-	EV / Sales 2025	365,559,272x
Free-Float	79.07%	Yield 2024 *	-	Yield 2025	-

1 day	+10.30%
1 week	-14.03%
Current month	-14.13%
1 month	-9.48%
3 months	-32.32%
6 months	-65.97%
Current year	-74.06%

1 week	13,200	17,340
1 month	13,200	18,970
Current year	13,050	63,500
1 year	13,050	74,900
3 years	13,050	74,900
5 years	13,050	74,900
10 years	13,050	74,900

Manager	Title	Age	Since
Tae-Kyo Park CEO	Chief Executive Officer	66	01/04/2015
Young-Seok Seo DFI	Director of Finance/CFO	69	01/06/2019
Yo-Seop Yu CTO	Chief Tech/Sci/R&D Officer	58	01/04/2021

Director	Title	Age	Since
Tae-Kyo Park BRD	Director/Board Member	66	01/04/2015
Yo-Seop Yu BRD	Director/Board Member	58	01/04/2021
Gyeong-Se Min BRD	Director/Board Member	65	01/04/2021

IntoCell, Inc. Stock

Stocks

A287840

KR7287840003

Biotechnology & Medical Research

Valuation: IntoCell, Inc.

Chart: IntoCell, Inc.

Latest news: IntoCell, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: IntoCell, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
15/7/25	Tae-Kyo Park	Buy	Founder	10,000	0.0674%
15/7/25	Tae-Kyo Park	Buy	Founder	26,000	0.1751%
28/5/25	Sun-Young Kim	Free		207,960	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTOCELL, INC.	+10.30%	-14.03%	-	-	168M
Average	+10.30%
Weighted average by Cap.	+10.30%

	2024	2025
Net sales	2.91K 2.18 1.94 1.8 1.64 3.08 207.48 3.13 21.59 8.47 108.17 8.2 8.02 344.89	2.3K 1.73 1.53 1.42 1.29 2.44 164.2 2.48 17.08 6.7 85.61 6.49 6.35 272.96
Net income	-9.91B -7.45M -6.61M -6.14M -5.58M -10.51M -708M -10.7M -73.66M -28.89M -369M -27.97M -27.38M -1.18B	-10.6B -7.97M -7.07M -6.56M -5.97M -11.24M -757M -11.44M -78.79M -30.9M -395M -29.92M -29.29M -1.26B
Net Debt	-2.15B -1.61M -1.43M -1.33M -1.21M -2.27M -153M -2.32M -15.95M -6.25M -79.91M -6.06M -5.93M -255M	-20.59B -15.48M -13.73M -12.74M -11.59M -21.82M -1.47B -22.21M -153M -59.99M -767M -58.09M -56.86M -2.44B